CRISPR

In the late 1980s and mid-1990s, genomes of diverse lineages of bacteria and archaea (the latter representing a domain of single-celled prokaryotic microorganisms) revealed clusters of regularly interspaced short palindromic repeats, known today under the abbreviation CRISPR. Later it was found that these repeat sequences (previously considered disparate) share a common set of features.

CRISPR-Based Diagnostics: The Future of Disease Detection

CRISPR-based diagnostics offer transformative solutions for disease detection, utilizing advanced gene-editing tools for precise and rapid molecular testing.

CPISPR Applications

How Does CRISPR Compare to Other Gene-Editing Techniques?

Understanding CRISPR Therapy

CRISPR-Cas14: Discovery, Function, Advantages

CRISPR-Cpf1

Unlocking the Potential: CRISPR-Cas9 Gene Editing in Liver Diseases

Could CRISPR Repair CFTR in Cystic Fibrosis Patients?

Uses of CRISPR/Cas Biosensing Systems

What is CRISPR/Cas9?

CRISPR: The End for Zinc Fingers?

CRISPR: Ethical and Safety Concerns

See more featured articles »

Manipulating RNA sequences using CRISPR-Cas13

Electroporation and the Production of Knockout Mice

Editing Sperm DNA using CRISPR

CRISPR Interference (CRISPRi) for Gene Suppression

Latest CRISPR News and Research

New workflow boosts nuclear delivery for safer gene therapy

Gene therapy holds the promise of preventing and curing disease by manipulating gene expression within a patient's cells. However, to be effective, the new gene must make it into a cell's nucleus.

5 Feb 2026

Advancing brain microphysiological systems for in vitro neurotoxicity and cognitive function testing

Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling.

From Yokogawa Life Science 3 Feb 2026

How conflicting MIC breakpoints distort antimicrobial resistance data

The review emphasizes that differing CLSI and EUCAST breakpoints complicate AMR tracking, calling for standardized criteria to enhance global health security.

3 Feb 2026

New diagnostic framework addresses challenges of rapidly-mutating RNA viruses

The rapid evolutionary dynamics of RNA viruses, driven by high mutation rates and the consequent formation of complex quasispecies populations, present a formidable obstacle to conventional molecular diagnostic approaches.

30 Jan 2026

ERC Proof of Concept grant supports promising CRISPR-based cancer treatment research

Microbiologist John van der Oost of Wageningen University & Research (WUR) has received an ERC Proof of Concept grant to further develop a promising CRISPR-based approach to cancer treatment. With funding of €150,000, he and researcher Christian Südfeld will spend the next eighteen months working on a method to kill cancer cells from within, while sparing healthy cells as much as possible.

30 Jan 2026

Research uncovers why certain brain cells are more resilient to tau protein buildup

New research by UCLA Health and UC San Francisco has uncovered why certain brain cells are more resilient than others to the buildup of a toxic protein that is a hallmark of Alzheimer's disease and related dementias, potentially leading to new targets for therapies or treatments.

30 Jan 2026

Brain protein CUL5 protects neurons by clearing toxic tau clumps

Researchers at UC San Francisco have identified a hazardous waste collector in the brain that disposes of the toxic clumps of tau protein that can lead to dementia.

28 Jan 2026

First topical CRISPR gene therapy corrects disease-causing mutations in human skin

Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the University of British Columbia are extending those possibilities to the skin for the first time.

27 Jan 2026

Purdue researchers discover new therapeutic target for triple-negative breast cancer

A Purdue University team led by Kyle Cottrell has discovered a new therapeutic target for triple-negative breast cancer.

27 Jan 2026

Study identifies a powerful strategy to overcome drug resistance in breast cancer

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast cancer by simultaneously targeting two key cell-cycle regulators, CDK2 and CDK4/6.

22 Jan 2026

ELRIG announces Drs Stephen Ward and Annarita Miccio as keynote speakers for Cell and Gene Therapy 2026

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speakers for Cell and Gene Therapy 2026. Drs Stephen Ward (Cell and Gene Therapy Catapult) and Annarita Miccio (Imagine Institute) will lead the inaugural two-day event taking place at Hinxton Hall in Cambridge, UK from 9-10 March.

20 Jan 2026

CRISPR-Cas3: A safer gene-editing tool shows promise for transthyretin amyloidosis treatment

Genetic disorders occur due to alterations in the primary genetic material, deoxyribonucleic acid (DNA), of an organism. Transthyretin amyloidosis (ATTR) is a progressive disorder involving amyloid deposits of misfolded transthyretin (TTR) proteins.

14 Jan 2026

Gene regulators could restore the aging body's ability to self-repair

As we age, we don't recover from injury or illness like we did when we were young. But new research from UCSF has found gene regulators - proteins that turn genes on and off - that could restore the aging body's ability to self-repair.

12 Jan 2026

Study identifies PUF60 as a critical vulnerability in triple negative breast cancer

Researchers at University of California San Diego have identified a previously unrecognized treatment target for triple‑negative breast cancer (TNBC), the most aggressive subtype of breast cancer.

12 Jan 2026

One Health action needed as environmental reservoirs fuel drug-resistant infections

Environmental antimicrobial resistance is turning rivers, soils, and even the air into hidden highways for "superbugs," according to a new review that calls for urgent, coordinated action across human, animal, and environmental health.

9 Jan 2026

CIRM awards $7.4 million to advance stem cell-based gene therapy for Friedreich's ataxia

The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a University of California San Diego team developing a first-of-its-kind stem cell-based gene therapy for Friedreich's ataxia, a rare inherited neurodegenerative disease that causes progressive loss of coordination, muscle strength, heart function and overall mobility.

8 Jan 2026

CRISPR Cas12a3: A precise tool to halt viral protein production

Across all domains of life, immune defenses foil invading viruses by making it impossible for the viruses to replicate. Most known CRISPR systems target invading pathogens' DNA and chop it up to disable and modify genes, heading off infections at the (cellular) pass.

7 Jan 2026

Researchers identify hundreds of genes essential for the development of brain cells

An international research team identified hundreds of genes essential for the development of brain cells, including one gene linked to a severe neurodevelopmental disorder not previously described.

5 Jan 2026

New method can help better assess precision genome editing technology

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St. Jude Children's Research Hospital. Significant amounts of time and resources spent improving CRISPR gene editing technology focus on identifying small off-target sites that pose a safety risk, which is also technically challenging.

2 Jan 2026

Artificial intelligence unlocks new frontiers in RNA drug design

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article published in Engineering titled "The Future of AI-Driven RNA Drug Development" by Yilin Yan, Tianyu Wu, Honglin Li, Yang Tang, and Feng Qian, explores how artificial intelligence (AI) can revolutionize RNA drug development, addressing current limitations and offering new opportunities for innovation.

31 Dec 2025